RIPK1 and ulcerative colitis: Above all, GlaxoSmithKline (GSK) and Denali Therapeutics have identified and optimized a set of RIPK1 inhibitors and several human clinical trials as treatments of inflammatory and neurodegenerative diseases from ulcerative colitis and rheumatoid arthritis to amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) have been initiated [43].